SEC Form 4 · accession 0001493152-26-043246
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K Equels
Officer — CEO & President · Director
Period of report
Sep 17, 2026
Accepted (ET)
Sep 18, 2026 · 8:30 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000946644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 17, 2026 | P | 24,000 | $0.208 | A | 126,822 | D |
Table II — derivative securities
No Table II lines on this filing.